Abstract：
The limited availability of a healthy donor cornea and the incidence of allograft failure led researchers to seek other corneal substitutes via tissue engineering. Exploring the trend of clinical trials of the cornea with the vision of tissue engineering provides an opportunity to reveal future potential corneal substitutes. The results of this clinical trial are beneficial for future study designs to overcome the limitations of current therapeutic approaches. In this study, registered clinical trials of bio-based approaches were reviewed for corneal regeneration on March 22, 2024. Among the 3955 registered trials for the cornea, 392 trials were included in this study, which categorized in three main bio-based scaffolds, stem cells, and bioactive macromolecules. In addition to the acellular cornea and human amniotic membrane, several bio-based materials have been introduced as corneal substrates such as collagen, fibrin, and agarose. However, some synthetic materials have been introduced in recent studies to improve the desired properties of bio-based scaffolds for corneal substitutes. Nevertheless, new insights into corneal regenerative medicine have recently emerged from cell sheets with autologous and allogeneic cell sources. In addition, the future perspective of corneal regeneration is described through a literature review of recent experimental models.
摘要：
健康供体角膜的有限可用性和同种异体移植失败的发生率导致研究人员通过组织工程寻求其他角膜替代品。探索具有组织工程视野的角膜临床试验趋势，为揭示未来潜在的角膜替代品提供了机会。该临床试验的结果有利于未来的研究设计，以克服当前治疗方法的局限性。在这项研究中,2024年3月22日,我们对基于生物的角膜再生方法的注册临床试验进行了审查.在3955项角膜注册试验中，这项研究包括392项试验，它分为三种主要的生物基支架，干细胞,和生物活性大分子。除了脱细胞角膜和人羊膜，几种生物基材料已被引入作为角膜基质，如胶原蛋白，纤维蛋白,和琼脂糖。然而,在最近的研究中已经引入了一些合成材料来改善用于角膜替代物的生物基支架的所需性能。然而，最近，自体和同种异体细胞来源的细胞片对角膜再生医学有了新的见解。此外,通过对最近的实验模型的文献回顾，描述了角膜再生的未来前景。
